Aurobindo Pharma gets USFDA approval for Ceftriaxone

MUMBAI: Drug maker Aurobindo Pharma on Friday said it has recieved US regulatory approval for two drug applications in that country used in the treatment of bacterial infection.

The company has received final approvals from the US Food and Drug Administration (US FDA) for two abbreviated new drug applications -- Ceftriaxone, Aurobindo Pharma said in a filing to the Bombay Stock Exchange.

Ceftriaxone injection would be available in the variant of USP 250 mg, 500 mg, 1 g and 2 g, it added.

The injections are Cephalosporins products under the anti-infective treatment, With this Aurobindo now has 72 ANDAs approved by the US FDA.

Shares of the company closed at Rs 286.40, up 2.71 per cent on the BSE.